Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Current Assets (2016 - 2025)

IGC Pharma (IGC) has disclosed Current Assets for 15 consecutive years, with $2.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Current Assets fell 52.85% to $2.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $2.0 million, a 52.85% decrease, with the full-year FY2025 number at $2.9 million, down 21.84% from a year prior.
  • Current Assets was $2.0 million for Q3 2025 at IGC Pharma, down from $2.2 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $23.5 million in Q1 2021 to a low of $2.0 million in Q3 2025.
  • A 5-year average of $9.4 million and a median of $6.1 million in 2023 define the central range for Current Assets.
  • Peak YoY movement for Current Assets: surged 68.44% in 2021, then crashed 61.7% in 2023.
  • IGC Pharma's Current Assets stood at $19.2 million in 2021, then plummeted by 51.37% to $9.4 million in 2022, then plummeted by 61.7% to $3.6 million in 2023, then decreased by 14.85% to $3.1 million in 2024, then tumbled by 34.32% to $2.0 million in 2025.
  • Per Business Quant, the three most recent readings for IGC's Current Assets are $2.0 million (Q3 2025), $2.2 million (Q2 2025), and $2.9 million (Q1 2025).